The global pharmaceutical and biotechnology sectors, integral components of the broader healthcare industry, are grappling with a significant environmental paradox:…
Read More
Amazon Bio Discovery cut MSK antibody design from a year to weeks, AWS says
Amazon Web Services (AWS) today unveiled Amazon Bio Discovery, a groundbreaking application designed to drastically accelerate the drug discovery process…
Read More
Immuto Scientific Pairs AI and Mass Spectrometry for a Step Change in Protein Structure Throughput
Immuto Scientific, a trailblazing company co-founded in 2018 by electrical engineers Faraz A. Choudhury, Ph.D. (CEO) and Daniel Benjamin, Ph.D.…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, currently buoyed by the explosive success of its GLP-1 franchise, has announced its intent to acquire…
Read More
EClinical Solutions study models 241% ROI from AI-powered clinical trial data platform
The pharmaceutical industry, perpetually challenged by the immense costs, protracted timelines, and inherent complexities of bringing new therapies to market,…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
The majority of these high-value collaborations, roughly half, involved firms of U.S. origin, predominantly structured as mergers and acquisitions (M&A).…
Read More
A decade in the making: How functional NAMs are redefining cardiac safety assessment
In recent years, the landscape of drug safety testing has undergone a profound transformation, marked by the rapid acceleration of…
Read More
BioNTech’s Dramatic Pivot: From Pandemic Powerhouse to Oncology Challenger Amidst Job Cuts and Shifting Fortunes
The German biotechnology firm BioNTech, once a beacon of innovation and a financial titan thanks to its pioneering mRNA COVID-19…
Read More
Deloitte report showed pharma returns rising to 7%. GLP-1s did most of the work.
The pharmaceutical industry, emerging from a period characterized by uneven growth and significant challenges in research and development (R&D) productivity,…
Read More
Canada Becomes First G7 Nation to Approve Generic Semaglutide Following Novo Nordisk Patent Lapse, Paving Way for Enhanced Access and Affordability
In a landmark decision poised to significantly reshape the pharmaceutical landscape for diabetes and obesity management, Health Canada has granted…
Read More
